Carcinoma, Hepatocellular Clinical Trials

20 recruiting

Carcinoma, Hepatocellular Trials at a Glance

20 actively recruiting trials for carcinoma, hepatocellular are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Houston, Jinan, and Boston. Lead sponsors running carcinoma, hepatocellular studies include Qilu Hospital of Shandong University, Shanghai Henlius Biotech, and Asan Medical Center.

Browse carcinoma, hepatocellular trials by phase

Treatments under study

About Carcinoma, Hepatocellular Clinical Trials

Looking for clinical trials for Carcinoma, Hepatocellular? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Hepatocellular trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Hepatocellular clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled11 locationsNCT07227012
Recruiting
Not Applicable

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

Carcinoma, HepatocellularCirrhosis
VA Office of Research and Development4,700 enrolled32 locationsNCT05486572
Recruiting
Phase 1

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Carcinoma, HepatocellularNeoplasms
Aptamer Sciences, Inc.70 enrolled4 locationsNCT06687941
Recruiting
Phase 2

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular
Asan Medical Center33 enrolled1 locationNCT07010497
Recruiting
Phase 2

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Carcinoma, HepatocellularLiver Cell Carcinoma
Rutgers, The State University of New Jersey35 enrolled2 locationsNCT05366829
Recruiting

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Carcinoma, Hepatocellular
The University of Texas Health Science Center at San Antonio84 enrolled1 locationNCT03894917
Recruiting
Phase 2

Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion

Carcinoma, Hepatocellular
University Hospital, Montpellier53 enrolled4 locationsNCT03727633
Recruiting
Phase 4

National Liver Cancer Screening Trial

Liver CancerCarcinoma, HepatocellularLiver Cirrhosis+1 more
University of Texas Southwestern Medical Center5,500 enrolled18 locationsNCT06084234
Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Pleural Effusion, MalignantAscites, MalignantCarcinoma+4 more
Travera Inc200 enrolled1 locationNCT05461430
Recruiting
Not Applicable

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

Carcinoma, Hepatocellular
Ochsner Health System50 enrolled1 locationNCT05953961
Recruiting
Phase 2

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Carcinoma, Hepatocellular
Shanghai Henlius Biotech90 enrolled1 locationNCT06742892
Recruiting
Phase 2

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

Carcinoma, HepatocellularGastric Adenocarcinoma
National University Hospital, Singapore360 enrolled1 locationNCT06422403
Recruiting
Phase 2

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Shanghai Henlius Biotech117 enrolled1 locationNCT06349980
Recruiting
Phase 1Phase 2

A Study of PTX-9908 Injection for Non-resectable HCC with TACE

Carcinoma, Hepatocellular
TCM Biotech International Corp.50 enrolled1 locationNCT03812874
Recruiting

Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma

Carcinoma, HepatocellularImmunotherapy
Qilu Hospital of Shandong University200 enrolled1 locationNCT06571396
Recruiting
Phase 2

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Carcinoma, Hepatocellular
Qilu Hospital of Shandong University30 enrolled1 locationNCT06454578
Recruiting
Not Applicable

Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma

Carcinoma, Hepatocellular
Taipei Veterans General Hospital, Taiwan450 enrolled1 locationNCT06384950
Recruiting

Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular
Qianfoshan Hospital92 enrolled1 locationNCT06365034
Recruiting

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Carcinoma, HepatocellularNon-Alcoholic Fatty Liver DiseaseCirrhosis, Liver+2 more
Ruijin Hospital20,000 enrolled1 locationNCT05870969
Recruiting
Phase 1Phase 2

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular
Abivax S.A.48 enrolled2 locationsNCT03897543